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significantly reduced by using the ETHICON SECURESTRAP™ Open fixation device 
compared with suture fixation of IPOM mesh. This shows promise of reducing open 
IPOM procedure time which may realize related patient benefits of reduced anesthe-
sia time, infection risks, costs etc. Also, reduction in surgical stress could potentially 
offer improvement in surgical performance – benefiting the surgeon, the patient 
and the health care system.
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Cost savings in tHe HUngarian Care Managing PrograMMe
Ágoston I., Vajda R., Jankó-Király A., Lampek K., Boncz I.
University of Pécs, Pécs, Hungary
Objectives: A pilot care managing programme was introduced in Hungary in 1999. 
The conceptual foundations of the Hungarian implementation of managed care is 
closer to what was called the GP fundholding in the UK than HMOs in the USA. The 
purpose of the study is to analyse the cost savings realized within the Hungarian 
care managing programme. MethOds: The data derive from the financial data-
base of the Hungarian National Health Insurance Fund Administration (NHIFA) 
covering the period 1999-2007. We identified the annual cost savings realized by 
the Care Managing Organizations. The Hungarian CMOs was financed through 
a risk adjusted capitation fee and the health services covered by CMOs were 
defined in legal regulations. Cost saving was defined as the difference between 
the annual revenues (capitation fee) and expenditures (real utilization) of care 
managing organizations. Results: During the study period the total number of 
persons covered by the care managing programme increased from 1.5 % of the 
Hungarian population to its peak of 19.4 % in 2005. The cost saving of the care 
managing programme was 63138000 Hungarian Forint (HUF) or 249756 Euro (EUR) 
in 1999; 457662600 HUF (1759945 EUR) in 2000, 1109442300 HUF (4322246 EUR) in 
2001; 2710926900 HUF (11157503 EUR) in 2002; 1452041100 HUF (5727683 EUR) in 
2003, 3799000306 HUF (15094804 EUR) in 2004; 3709400000 HUF (14954510 EUR) in 
2005; 4964600000 HUF (18786048 EUR) in 2006 and 3669000000 HUF (14599437 EUR) 
in 2007. These amounts resulted in the following annual savings rate: 1999: 3.6%; 
2000: 10.4%; 2001: 6.5%; 2002: 8.7%; 2003: 3.4%; 2004: 4.0%; 2005: 2.1%; 2006: 2.9% and 
2007: 2.9%. cOnclusiOns: With the development of the Hungarian care managing 
system, the average number of enrolees increased. Cost savings of Care Managing 
Organizations varied between 2.1-4.0 % during the mature period of this programme.
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systeMatiC review on tHe iMPaCts of striCt PHarMaCeUtiCal PriCe 
Controls
Relakis J.1, Maniadakis N.1, Kourlaba G.2, Shen J.3, Holtorf A.P.4
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
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Strategies LLC, Basel, Switzerland
Objectives: To systematically review and synthesize published evidence on the 
impact of pharmaceutical price controls, such as price cuts, price caps, price freezes 
or international price referencing. MethOds: A literature search was conducted 
in Medline, Scopus, Econlit, Web of Science and ABI/INFORM to identify relevant 
studies published in English to March 2013. Results: Forty-seven out of 3787 initial 
studies were included. Price caps and price reductions were most commonly studied 
in the literature, followed by reference pricing and price freezes. The evidence indi-
cates that price controls reduce company profits and have a detrimental effect on 
pharmaceutical research and development, pipeline productivity and investment. 
They may also inhibit, reduce or delay new product launches, increase parallel 
exports and diminish availability of generics due to disincentives and, hence, may 
reduce product availability, increase withdrawals and shortages. In terms of public 
expenditure about half of the studies indicate realized savings, but the other half 
indicate no effect or even increases in expenditure. In terms of effects on patients, 
studies indicate in the short term welfare gains due to lower cost and better access, 
but also losses due to drug shortages and availability issues. Long-term effects 
appear to be welfare losses due to reductions of discoveries, resulting from the 
disinvestment associated with the lower revenues. cOnclusiOns: Effects of price 
controls are ambiguous in the case of pharmaceuticals. Price controls reduce drug 
acquisition cost and increase access in the short run. On the other hand, they may 
decrease patient welfare and access as they can cause product shortages, withdraw-
als and launch delays. Moreover, they may reduce the likelihood for new product dis-
coveries. Contrary to common beliefs, price controls not always reduce expenditure. 
Thus careful consideration is needed in designing drug price policies. Value based 
pricing approaches may be more effective alternatives compared to price cutting.
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gUidanCe for PartnersHiP working Between CatsalUt and tHe 
PHarMaCeUtiCal indUstry
Gilabert A., Espinosa C., Mora R., Santos J.
Catalan Autonomous Region Health Service, Barcelona, Spain
Objectives: Relationships between National/Regional Health care Systems (NHS) 
and pharmaceutical companies can and should be based on a cooperative venture, 
built on the expertise of each side, that best meets clearly defined public needs 
through the appropiate allocation of resources, risks and rewards, while preserv-
ing transparency and its independence. However, joint working can be difficult to 
initiate due to the number of parties involved and the lack of clear shared objec-
tives. Guidelines can be very useful to support the NHS/Pharmaceutical Partner’s 
commitment. To our knowledge, there are no such published guidelines in Spain. 
This first guidance in Spain was designed with the main aim of identifying and 
simplifying the initiation, the start-up phase and the remainder of joint working 
projects between the Catalan Heath System (CatSalut) and pharmaceutical com-
panies. MethOds: A flowchart was designed to describe the standard steps and 
timelines suggested to start, implement, monitor and evaluate a Joint Working pro-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study was 
to analyze trends in the use of health economic information for developing clinical 
guidelines. MethOds: To understand trends in use of health economic information 
we conducted targeted search for clinical guidelines, expert recommendations, and 
consensus statements with specific mention of “cost” or “economic” or related terms. 
A systematic literature search was undertaken for the databases Pubmed, Google 
Scholar and Cochrane. The guidelines published between 2003-2012 were included. 
For guidelines which met the search criteria, data was collected for the name of the 
authors, indication, year of publication, country/region, and context of use of cost/eco-
nomic evidence. Results: Sixteen clinical guidelines published between 2003-2012 
met the inclusion criteria for specific mention of cost/economic evidence. More than 
50% of these guidelines were published between 2006-2012. For indication, 3 out of 
16 guidelines were for diabetes, while the rest were for different indications. In these 
16 guidelines “cost effectiveness” was mentioned 14 times, either referencing cost-
effectiveness data or to mention the importance of such data for selecting treatment 
options. The guidelines commonly cite high cost of disease or high economic burden 
as one of the considerations for developing new recommendations (11 out of 16). 
Another term that was commonly used by these guidelines was “cost-benefit,” which 
was mentioned 5 times in these guidelines. Notably, QALY was rarely mentioned (1 
out of 16 times) in these guidelines. cOnclusiOns: This analysis suggests that some 
clinical experts groups are increasingly showing willingness to use and incorporate 
health economic information for developing new recommendations.
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reasons given By tHe eUroPean MediCines agenCy for revising 
disease-sPeCifiC sCientifiC gUidelines
Caron M., Acquadro C.
Mapi Research Trust, Lyon, France
Objectives: To review all the reasons provided by the European Medicines Agency 
(EMA) to substantiate the need for revisions to or updates of disease-specific scien-
tific guidelines developed by the Committee for Medicinal Products for Human Use 
(CHMP). MethOds: All the scientific guidelines issued by the CHMP were reviewed 
on the EMA’s website. The guidelines not focusing on disease-specific issues were 
not selected, i.e., guidelines listed in the following sections: Clinical Pharmacology 
and pharmacokinetics, General, Herbal Medicinal products, Information on medici-
nal products, and Radiopharmaceutical and diagnostic agents. Results: A total of 
182 disease-specific scientific guidelines were reviewed. The review identified 21 
concept papers developed with the intent of revision (11.5% of specific guidelines). 
The analysis of the concept papers revealed that four main reasons were claimed: 
1) Clarifications needed for pediatric development [10 concept papers: acute heart 
failure, asthma, Crohn’s disease, hepatitis C, hypertension, glucocorticoid-induced 
osteoporosis, irritable bowel syndrome (IBS), multiple sclerosis, pain, and ulcerative 
colitis); 2) Evolution in the field and treatments (n= 9); 3) Clarifications on endpoints 
identification and measurement (n= 7); and 4) Safety aspects (n= 6). For instance, 
in asthma, one of the critical aspects to be discussed regarding endpoints was “the 
need to reinforce the use of clinical measurements (symptoms) and patient-reported outcome 
measures to complement lung-function parameters.” In IBS, regulators asked that “An 
evaluation whether more clear recommendations as regards the use of certain 
scales or newly developed PROs can be made is also desirable.” cOnclusiOns: The 
main reason for the EMA to revise disease-specific guidelines is the need for provid-
ing guidance in pediatric issues. This is in line with the introduction of Pediatric 
Investigation Plans (PIPs) by the European Commission in January 2007 to help 
ensure that medicines for children are included in the mainstream drug develop-
ment process in Europe.
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redUCtion in fixation tiMe and related sUrgiCal stress witH tHe 
Use of etHiCon seCUrestraP™ oPen aBsorBaBle straP fixation deviCe 
in tHe dePloyMent of intra-Peritoneal onlay MesH (iPoM) for oPen 
ventral Hernia rePair
Roy S.1, Shnoda P.2, Savidge S.2, Hammond J.2, Panish J.1, Wilson M.3
1Johnson & Johnson Global Surgery Group, Somerville, NJ, USA, 2Ethicon, Somerville, NJ, USA, 
3University of Exeter, Exeter, UK
Objectives: This study compared fixation time using ETHICON SECURESTRAP™ 
Open device to suture fixation of IPOM mesh in ventral/ incisional hernia repair. It 
also assesses surgeon-reported levels of task load experienced during the two fixa-
tion approaches. MethOds: Nine surgeons inserted skirted mesh using IPOM tech-
nique on created incisional defects in live swine models. Each surgeon performed 
two suture (using their standard technique) and two ETHICON SECURESTRAP™ 
Open fixation procedures. The duration of fixation procedure starting from mesh 
preparation through the last firing or suture knot was recorded. Surgical work-
load was measured using the validated Surgery Task Load Index (SURG-TLX) 
questionnaire. Time savings and task load reduction were determined by the 
lower limit of the two-sided 95% confidence interval for the difference between 
suture fixation and ETHICON SECURESTRAP™ Open groups. Results: A total of 
38 IPOM fixation procedures were performed with equal numbers using suture 
and ETHICON SECURESTRAP™ Open. 89% reduction in mean fixation time was 
observed from suture to mechanical fixation with ETHICON SECURESTRAP™ Open 
[mean reduction: 34.9 minutes (SD: 17.9 minutes); p< 0.0001]. Similarly, 55% reduc-
tion in perceived overall workload was observed with SECURESTRAP™ Open com-
pared to suture fixation [mean reduction: 22.17 (SD: 15.12); p= 0.0003]. ETHICON 
SECURESTRAP™ Open demonstrated significantly lower ratings in five of the six ele-
ments of surgical task load, namely – Mental Demand, Physical Demand, Situational 
Stress, Task Complexity, and Temporal Demand [p< 0.05 for all] compared to suture 
fixation. cOnclusiOns: Time for fixation and related surgical task load can be 
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when and for what type of service use publicly financed health care. MethOds: 
Data was retrieved from National Health Insurance Fund Administration of Hungary 
(NHIFA) and Central Statistical Office. Current study’s base was processing the last 
five years’ statistical data (2007-2012), concerning health care of third country 
citizens permanently living in Hungary. We analyzed the volume, place and medi-
cal specialty of these services. Results: In the last 5 years third country citizens 
required inpatient care 9414 times (61% in Budapest), emergency care 11776 times 
(63% in Budapest), out-patient care 72306 times (57% in Budapest). Patient accessed 
health care providers due to medical problems in the following medical fields: 
obstetrics (19%), surgery (18%), laboratory (18%), pediatrics (7%), and ophthalmol-
ogy (6%). Most of the patients are from Ukraine (42 %), China (22 %), Vietnam (11 %), 
ex-Yugoslavia (6 %) and Russia (6 %). Analysis by nationalities shows that Chinese 
population requires health care relatively few times (for instance, 2011: 5%, in 2012: 
6%) and even these are almost exclusively done in Budapest. In contrast USA citizens 
see doctors relatively often (2011: 8%, 2012: 8%), mainly in relation to diagnostics and 
curative surgery. From the neighboring non-EU states (23095 people, 31%) Ukrainian 
and (5709 people, 7%) ex-Yugoslavian citizens needed health care in the investigated 
period. Despite previous expectations, need for health care is not the characteristics 
of border regions but the capital city. cOnclusiOns: Utilization of the Hungarian 
publicly financed health care system is significant by third country citizens. When 
planning health care capacity, this crucial fact must be taken into consideration.
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PHarMaCeUtiCal regUlation in eUroPe and its iMPaCt on CorPorate 
r&d
Mahlich J.1, Eger S.2
1University of Vienna, Vienna, Austria, 2Medical University of Vienna, Vienna, Austria
Objectives: Many European countries regulate drug prices in order to cope with 
rising health expenditures. On the other hand, price regulation distorts incentives to 
invest in pharmaceutical R&D. This study aims at empirically assessing the impact 
of price regulation on pharmaceutical R&D expenditures. MethOds: We analyze 
a sample of 20 leading pharmaceutical companies between 2000 and 2008. The 
share of sales in Europe serves as a proxy for the degree of price regulation. We 
control for other determinants of R&D such as cash flow, company size, leverage 
ratio, growth rate, and Tobin’s q. Results: Our results suggest a nonlinear rela-
tionship between European sales ratio and R&D intensity. Beyond a threshold of 
33% of sales generated in Europe, a higher presence in Europe is associated with 
lower R&D investments. cOnclusiOns: Price regulation has a negative impact 
on pharmaceutical R&D investments. Policy makers must take long term effects 
of regulation into account.
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eliCiting tHe relative iMPortanCe of key eleMents for Benefit-
risk assessMent: a CoMParison aMong general PoPUlation, HealtH 
aUtHority and MediCal doCtors
Ha J.H.1, Na H.S.1, Chung M.W.1, Byun J.H.2, Kwon S.H.2, Park E.J.3, Lee E.K.2
1Ministry of Food and Drug Safety, Chungcheongbuk-do, South Korea, 2Sungkyunkwan University, 
Suwon, South Korea, 3Korea Institute for Health and Social Affairs, Seoul, South Korea
Objectives: This research was designed to find out the key attribute for ben-
efit-risk assessment using swing weight method in general population, health 
authority and hospital doctors. MethOds: We selected six important elements 
for each benefit and risk assessment based on previous study. The elements of 
benefit assessment consisted of disease severity, size of population affected by 
disease, clinical guidelines recommendation, comparative interventions limita-
tion, improvement of efficacy/effectiveness, improvement of quality of life. The 
attributes of risk assessment contained overall incidence of adverse events, 
overall incidence of serious adverse events, discontinuation rate due to adverse 
events, drug or food interactions, drugs of potential misuse, risk management. 
583 subjects constituted 3 groups (general population, health authority and hos-
pital doctors) were selected across the country by quota sampling method and 
performed survey to evaluate preference of each elements with the swing methods 
repeatedly. The trained interviewers assisted participant successfully completed 
survey. Results: Improvement of efficacy/effectiveness and overall incidence 
of serious adverse events were revealed as the most important attributes than 
others for benefit- risk assessment in all three groups. Health authority group 
outweighed the improvement of efficacy/effectiveness [Mean (±SD): 0.208(±0.04)] 
and overall incidence of serious adverse events [Mean (±SD): 0.220(±0.05)], while 
0.204(±0.03), 0.216(±0.04) in doctor group and 0.197(±0.04), 0.185(±0.04) in general 
population respectively. In six benefit attributes, the lowest preference score was 
clinical guidelines recommendation [0.114(±0.04)] in health authority group and 
[0.144(±0.04)] in general population while size of population affected by disease 
[0.126(±0.04)] in hospital doctor group. Among six risk elements, the lowest prefer-
ence was drugs of potential misuse showed in health authority [0.117(±0.04)] and 
in hospital doctors [0.121(±0.04)] while risk management [0.121(±0.04)] in general 
population. cOnclusiOns: This shows that improvement of efficacy/effective-
ness among benefit attributes and overall incidence of serious adverse events 
among risk attributes are key elements for benefit-risk assessment.
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Coverage witH evidenCe develoPMent in sweden – forMality or 
effeCtive way to redUCe UnCertainty?
Kornfeld A.1, Schroeder M.2, Toumi M.3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, Copenhagen, Denmark, 3University Claude 
Bernard Lyon 1, Lyon, France
Objectives: TLV (formerly LFN) is responsible for reimbursement decisions in 
Sweden. They regularly give temporary reimbursement with request for additional 
ject, applicable to both single and multi-company projects. Any obligatory internal 
processes should be completed in tandem. Results: Health outcomes studies, 
pharmacoeconomic evaluations, and risk sharing agreements for the access of new 
pharmaceuticals were identified as projects of high priority to implement in the 
following years. cOnclusiOns: The steps outlined in this guidance, although not 
compulsory, will provide useful practical tips for how to go about setting up a Joint 
Working project in Catalonia (Spain), and to assist through the remainder of it. This 
guide is not a substitute for suitable regulatory or legal advice.
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Objectives: In the context of increasing demand and expenditure for health 
services it is important to elaborate policies which maximise efficiency. 
Pharmaceuticals account for about a fifth of total health care expenditure and are 
often target of health care efficiency policies. The aim of this study is to classify 
and grade pharmaceutical supply and demand control policies across the globe 
and cluster systems by regulatory rigidity. MethOds: Pharmaceutical policies and 
market data across 65 countries were researched in the literature with emphasis 
on pricing, reimbursement, dispensing, expenditure and demand control domains. 
Policies were classified by domains and graded through a multi-country expert sur-
vey for the degree of regulation. Cluster analysis helped to group countries by policy 
types. Results: Pricing policies for on-patent products (with increasing degree 
of regulation) include: free pricing, direct negotiations, value-based-pricing, cost-
plus-pricing, conditional-pricing, reference-pricing, state dictates and tenders. Cost 
control policies include: discounts, rebates, risk-sharing agreements, price-volume 
agreements, profit controls, pay-backs, claw-backs, margin cuts, price cuts, freezes, 
and tenders. Reimbursement policies include: variants of ATC5-based internal refer-
encing, variants of statutory copayments, and variants of ATC4-based internal refer-
encing. Dispensing policies were: no restrictions, indicative substitution, mandated 
or compulsory substitution. Demand controls include: educational campaigns, 
prescription aids, indicative prescription guidelines, indicative INN prescription, 
prescription monitoring, quotas, targets, predefined budgets, compulsory INN pre-
scription, mandatory electronic prescription, compulsory prescription guidelines, 
prior/posterior approvals, sanctions and incentives for target/guidelines adherence. 
Cluster analysis identified a set of countries using an intermediate regulation policy 
approach and another with a more rigid approach. These did not differ significantly 
(p: 0.20) concerning pharmaceutical expenditure as % of GDP. cOnclusiOns: A 
variety of policies were used in recent years for controlling pharmaceutical expen-
ditures. Countries fall into two subsets based on the intensity of the regulation. 
More regulated systems do not appear to be associated with lower pharmaceutical 
expenditure.
PHP202
tHe Cost-effeCtiveness of PeriodiC safety UPdate rePorts (PsUrs) for 
BiologiCals in eUroPe
Bouvy J.1, Ebbers H.2, Schellekens H.2, Koopmanschap M.A.3
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Utrecht University, Utrecht, The 
Netherlands, 3Erasmus University, Rotterdam, The Netherlands
Objectives: The safety profile of new drugs is usually not fully established upon 
market entry, giving cause for Europe’s comprehensive pharmacovigilance sys-
tem. A key regulatory vehicle to communicate the outcomes of pharmacovigilance 
activities is the Periodic Safety Update Report (PSUR), which summarizes a prod-
uct’s worldwide safety data and facilitates periodic assessment of its benefit-risk 
profile. We assessed the cost-effectiveness of all PSURs submitted in Europe during 
1995-2009 for biologicals, using a societal perspective. MethOds: We evaluated 
two regulatory scenarios: Full Regulation (pharmacovigilance including PSURs) and 
Limited Regulation (pharmacovigilance without PSURs). We assessed the source 
of regulatory action for all urgent safety issues that were identified for biologicals 
during 1995-2009. In two out of 24 urgent safety issues (systemic spread of botu-
linum toxin and edema after use of dibotermin-alfa), PSURs were the regulatory 
instrument that identified the safety issue and we assumed these issues would 
have been discovered five years later under limited regulation. Estimates from the 
literature and Markov-chain life tables were used to calculate costs and effects 
of PSURs for biologicals. Results: The incremental cost-effectiveness ratio (ICER) 
of Full Regulation versus Limited Regulation was € 342,110 per quality-adjusted 
life year gained. Extensive sensitivity analyses indicated a low probability of the 
Full Regulation scenario being cost-effective. Only two parameters resulted in a 
more favorable ICER: a 100% risk reduction after identification of the urgent safety 
issues (base-case assumption was 25%) and a high risk (1 in 1,000 patients) of severe 
systemic spread after therapeutic use of botulinum toxin (base-case assumption 
1 in 10,000 patients). cOnclusiOns: Regulatory cost-effectiveness analysis is a 
feasible instrument for assessing the (added) value of parts of the drug regulatory 
framework. In light of high costs of regulatory compliance, cost-effectiveness should 
be a consideration in deciding whether or not safety-related regulatory actions 
are required.
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Utilization of tHe HUngarian PUBliCly finanCed HealtH Care systeM 
By tHird (non eU) CoUntry Citizens
Kovács G.1, Boncz I.2, Gyeney L.3
1Széchenyi István University, Győr, Hungary, 2University of Pécs, Pécs, Hungary, 3Pázmány Péter 
Catholic University, Budapest, Hungary
Objectives: The number of citizens from third countries (outside of European 
Union or stateless) permanently living in Hungary is 205 000, and annually ca. 23000 
people get permit to settle. Current study aims at exploring what group of foreigners, 
